* Lamberto Andreotti, Elliott Sigal, and Jean-Marc Huet will join James M. Cornelius, chairman and chief executive officer, on the company’s newly-formed Executive Committee, which will be the company’s senior strategy and decision-making body.
Mr. Andreotti was today appointed president and chief operating officer, and elected a member of the company’s Board of Directors.
Dr. Sigal, the company’s executive vice president, chief scientific officer and president, Research & Development, oversees the company’s research, discovery, and development functions.
Mr. Huet, today promoted to executive vice president and chief financial officer, will also oversee the areas of strategy and productivity in addition to finance.
“This group will chart the future for Bristol-Myers Squibb,” said Mr. Cornelius. “Our transformation over the past 15 months has been swift and seamless, and we will continue to move forward as a company purely focused on helping patients prevail against serious disease.”
In other changes announced today by Mr. Cornelius,
* Anthony Hooper has been named president, Americas; * Beatrice Cazala has been named president, Global Commercialization, and president, Europe; * John Celentano has been named president, Emerging Markets and Asia-Pacific; * Carlo De Notaristefani has been named president, Technical Operations and Global Support Functions; and * Giovanni Caforio has been named senior vice president, Global and U.S. Oncology.
Contact:
Bristol-Myers Squibb Company Media: Tracy Furey, 609-252-3208 tracy.furey@bms.com or Investors: John Elicker, 609-252-4611 john.elicker@bms.com
